InterVenn offers comprehensive glycoproteomic services with a new platform called perspectIV™.
The perspectIV platform offers new insights into cellular and protein function through characterization of glycoproteins. The key advantage of investigating the glycoproteome, as compared to the proteome, is that it provides access to a layer of biology, post-translational glycosylation, which importantly affects protein function in health and disease, adding orders of magnitude richer information about biology.
perspectIV is the first commercially available platform capable of rapidly and comprehensively interrogating glycosylation across the proteome, hypothesis-free or targeted, from serum, plasma, or tissue.CONTACT US TO LEARN MORE.
Powered by AI and advanced machine learning techniques, InterVenn’s perspectIV platform, can do in minutes what would take a human operator months to achieve.
Glycoproteomics, cutting-edge mass spectrometry, AI machine learning
Biomarker Discovery (Contract Research Services, data analysis, informatics support, multi-omic data integration)
Clinical Laboratory (CLIA laboratory, LDT validation, trials and regulatory support)
Commercialization (support send-out testing, commercial sales, customer-excellence team)
InterVenn's multidisciplinary glycoproteomic expertise seamlessly integrates novel insights into your research.
Accessioning and Extraction
Sample Preparation and Enzymatic Digestion
Separation and Identification by Liquid Chromatography-Mass Spectrometry (LCMS)
Proprietary AI & Machine Learning
InterVenn has developed a complete "sample to result" glycoproteomic solution.
Our scientists simplify the process to analyze and work with your team to help interpret the data.
Intervenn’s fully integrated services, tailored to your needs, help you achieve your research objectives. Accelerate your research by leveraging our expertise to deliver immediate insights.CONTACT US TO DISCUSS YOUR PROJECT.
Glycosylation is a post-translational language of biology, and InterVenn’s platform enables interrogation of the glycosylation status of any protein.
PSA is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in male subjects’ blood. The blood level of PSA is often elevated in men with prostate cancer even though other conditions such as prostatitis (inflammation of the prostate) and benign prostatic hyperplasia BPH may cause PSA elevations.
In a study by Hoffman et al., typical PSA tests, which only measure the abundance of the PSA protein, had an area-under-curve ‘AUC’ of 0.60 as depicted in figure on the right. Top figure shows an illustration of the PSA Protein structure.
In another study by Llop et al., glycosylatedPSA were shown to be differentially expressed in prostate cancer cohort when compared to the BPH cohort. Measuring core fucosylation and sialylation reported an AUC of 0.94 as depicted in the figure on the right. Bottom figure shows an illustration of the PSA protein structure with glycans.
Get to know more about Intervenn’s comprehensive glycoproteomics services and how they can facilitate your clinical research.